Vol 3, No 2 (June 2014): Chinese Clinical Oncology (The Changing World of Drug Development - Guest Editor: Christian Dittrich)

Review Article

The spectrum of clinical trials aiming at personalizing medicine
Christophe Le Tourneau, Maud Kamal, Marie Alt, Loic Verlingue, Vincent Servois, Marie-Paule Sablin, Nicolas Servant, Xavier Paoletti
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine
Sumithra J. Mandrekar, Daniel J. Sargent
Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development
Jens Hoffmann
From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer
Sophie Doisneau-Sixou, Nadia Harbeck
Functional and molecular imaging in cancer drug development
Vikram Rao Bollineni, Sandra Collette, Yan Liu
New challenge of developing combined radio-drug therapy
Philippe Maingon, Anne-Sophie Govaerts, Sofia Rivera, Conchita Vens, Emad Shash, Vincent Grégoire
The changing world of drug development: an academic research organization’s perspective on the “Seven Wonders” of the future world of anticancer drug development
Yan Liu, Denis Lacombe, Roger Stupp
The changing world of oncology drug development—A global pharmaceutical company’s perspective
Susan Galbraith
Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law
Duane Schulthess, Magda Chlebus, Richard Bergstrӧm, Karin Van Baelen
The changing world of cancer drug development: the regulatory bodies’ perspective
Iordanis Gravanis, Camille Vleminckx, Bertil Jonsson, Francesco Pignatti
The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer
Nils Wilking, Ulla Wilking, Bengt Jönsson
And now for something completely different: drugs that work!—The patients’ perspective
Peter Kapitein